Study findings suggest that patients with advanced/metastatic NSCLC have improved survival outcomes after receiving treatment that was guided by biomarker testing, according to research presented at…
In patients with advanced NSCLC that lack targetable mutations, pembrolizumab combined with chemo has shown promising results, according to research presented at the NCCN annual conference.
Patients with advanced/metastatic NSCLC have improved survival after treatment guided by biomarker testing, according to research presented at the NCCN Annual Conference.
In a study presented at the NCCN annual congress, Gel-LA was more likely to suppress testosterone rates over an extended period of time than Msphere-LA.
Patients with NHL with intermediate risk for FN maintain that risk even with pegfilgrastim prophylaxis, according to research presented at the NCCN Annual Conference.
Study findings have led experts to suggest that comorbidities in patients with non-Hodgkin’s lymphoma do not present randomly, but have distinct patterns, according to research presented at the NCCN…
Findings from a study presented at the NCCN Virtual Annual Congress found that regular DBHI for RNI-rBC improved lung and liver parameters.
The current protocol for monitoring the response to chemo in patients with ALL is a bone marrow biopsy, but a better one may exist, according to data presented at the NCCN Annual Conference.
Stay in the know.
OncNet Newsletter